[1]
|
Zhang, W., Girard, L., Zhang, Y.A., et al. (2018) Small Cell Lung Cancer Tumors and Preclinical Models Display Het-erogeneity of Neuroendocrine Phenotypes. Translational Lung Cancer Research, 7, 32-49.
https://doi.org/10.21037/tlcr.2018.02.02
|
[2]
|
Guo, H., Li, L. and Cui, J. (2020) Advances and Challenges in Im-munotherapy of Small Cell Lung Cancer. Chinese Journal of Cancer Research, 32, 115-128. https://doi.org/10.21147/j.issn.1000-9604.2020.01.13
|
[3]
|
徐瑜, 白莉. 广泛期小细胞肺癌免疫治疗新理念[J]. 中华肺部疾病杂志(电子版), 2021, 14(4): 407-411.
|
[4]
|
Mathieu, L., Shah, S., Pai-Scherf, L., et al. (2021) FDA Ap-proval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer. Oncologist, 26, 433-438.
https://doi.org/10.1002/onco.13752
|
[5]
|
徐张闻笛, 黄华艳, 夏立亮, 等. 广泛期小细胞肺癌免疫治疗疗效预测和增敏策略[J]. 实用肿瘤杂志, 2022, 37(6): 495-500. https://doi.org/10.13267/j.cnki.syzlzz.2022.084
|
[6]
|
Savage, P.A., Leventhal, D.S. and Malchow, S. (2014) Shaping the Repertoire of Tumor-Infiltrating Effector and Regulatory T Cells. Immunological Reviews, 259, 245-258. https://doi.org/10.1111/imr.12166
|
[7]
|
Becker, J.C., Andersen, M.H., Schrama, D. and thor Straten, P. (2013) Immune-Suppressive Properties of the Tumor Microenvironment. Cancer Immunology, Immunotherapy, 62, 1137-1148. https://doi.org/10.1007/s00262-013-1434-6
|
[8]
|
Ott, P.A., Elez, E., Hiret, S., et al. (2017) Pembrolizumab in Pa-tients with Extensive-Stage Small-Cell Lung Cancer: Results from the Phase Ib KEYNOTE-028 Study. Journal of Clini-cal Oncology, 35, 3823-3829.
https://doi.org/10.1200/JCO.2017.72.5069
|
[9]
|
Liu, S.V., Reck, M., Mansfield, A.S., et al. (2021) Updated Over-all Survival and PD-L1 Subgroup Analysis of Patients with Extensive-Stage Small-Cell Lung Cancer Treated with Ate-zolizumab, Carboplatin, and Etoposide (IMpower133). Journal of Clinical Oncology, 39, 619-630. https://doi.org/10.1200/JCO.20.01055
|
[10]
|
Goldman, J.W., Dvorkin, M., et al. (2021) CASPIAN Investigators. Durvalumab, with or without Tremelimumab, plus Platinum-Etoposide versus Platinum-Etoposide Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): Updated Results from a Randomised, Controlled, Open-Label, Phase 3 Trial. Lancet Oncology, 22, 51-65. https://doi.org/10.1016/S1470-2045(20)30539-8
|
[11]
|
Foster, N.R., Qi, Y., Shi, Q., et al. (2011) Tumor Response and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Extensive Stage Small-Cell Lung Cancer: Findings on the Basis of North Central Cancer Treatment Group Trials. Cancer, 117, 1262-1271. https://doi.org/10.1002/cncr.25526
|
[12]
|
Schiller, J.H., Adak, S., Cella, D., et al. (2001) Topotecan versus Observa-tion after Cisplatin plus Etoposide in Extensive-Stage Small-Cell Lung Cancer: E7593—A Phase III Trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 19, 2114-2122. https://doi.org/10.1200/JCO.2001.19.8.2114
|
[13]
|
Jett, J.R., Schild, S.E., Kesler, K.A. and Kalemkerian, G.P. (2013) Treatment of Small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 143, e400S-e419S. https://doi.org/10.1378/chest.12-2363
|
[14]
|
Noda, K., Nishiwaki, Y., Kawahara, M., et al. (2002) Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer. New England Journal of Medi-cine, 346, 85-91.
https://doi.org/10.1056/NEJMoa003034
|
[15]
|
Hermes, A., Bergman, B., Bremnes, R., et al. (2008) Irinotecan plus Carboplatin versus Oral Etoposide plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial. Journal of Clinical Oncology, 26, 4261-4267.
https://doi.org/10.1200/JCO.2007.15.7545
|
[16]
|
Zatloukal, P., Cardenal, F., Szczesna, A., et al. (2010) A Multicen-ter International Randomized Phase III Study Comparing Cisplatin in Combination with Irinotecan or Etoposide in Pre-viously Untreated Small-Cell Lung Cancer Patients with Extensive Disease. Annals of Oncology, 21, 1810-1816. https://doi.org/10.1093/annonc/mdq036
|
[17]
|
Rossi, A., Di Maio, M., Chiodini, P., et al. (2012) Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Indi-vidual Patient Data. Journal of Clinical Oncology, 30, 1692-1698. https://doi.org/10.1200/JCO.2011.40.4905
|
[18]
|
Ogino, H., Hanibuchi, M., Kakiuchi, S., et al. (2016) Analysis of the Prognostic Factors of Extensive Disease Small-Cell Lung Cancer Patients in Tokushima University Hospital. The Journal of Medical Investigation, 63, 286-293.
https://doi.org/10.2152/jmi.63.286
|
[19]
|
Goldie, J.H. and Coldman, A.J. (1979) A Mathematic Model for Relating the Drug Sensitivity of Tumors to Their Spontaneous Mutation Rate. Cancer Treatment Reports, 63, 1727-1733.
|
[20]
|
Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Re-views Cancer, 12, 252-264. https://doi.org/10.1038/nrc3239
|
[21]
|
Harvey, R.D. (2014) Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer. Clinical Pharmacology & Therapeutics, 96, 214-223. https://doi.org/10.1038/clpt.2014.74
|
[22]
|
Oh, D.Y. and Fong, L. (2021) Cytotoxic CD4+ T Cells in Cancer: Ex-panding the Immune Effector Toolbox. Immunity, 54, 2701-2711. https://doi.org/10.1016/j.immuni.2021.11.015
|
[23]
|
Haanen, J.B.A.G. and Robert, C. (2015) Immune Checkpoint Inhibitors. In: Michielin, O. and Coukos, G., Eds., Immuno-Oncology. Progress in Tumor Research, Vol. 42, Karger Publishers, Basel, 55-66.
https://doi.org/10.1159/000437178
|
[24]
|
Ahn, M.J. (2019) Discussion: One Step Further toward Filling the Gap. IASLC World Conference on Lung Cancer, Barcelona, 7-10 September 2019.
|
[25]
|
Reck, M., Luft, A., Szczesna, A., et al. (2016) Phase III Randomized Trial of Ipilimumab plus Etoposide and Platinum versus Placebo plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. Journal of Clinical Oncology, 34, 3740-3748. https://doi.org/10.1200/JCO.2016.67.6601
|
[26]
|
Horn, L., Mansfield, A.S., Szczęsna, A., et al. (2018) First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. New England Journal of Medicine, 379, 2220-2229.
https://doi.org/10.1056/NEJMoa1809064
|
[27]
|
Rudin, C.M., Awad, M.M., Navarro, A., et al. (2020) Pembroli-zumab or Placebo plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Ran-domized, Double-Blind, Phase III KEYNOTE-604 Study. Journal of Clinical Oncology, 38, 2369-2379. https://doi.org/10.1200/JCO.20.00793
|
[28]
|
Gadgeel, S.M., Pennell, N.A., Fidler, M.J., et al. (2018) Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). Journal of Thoracic Oncology, 13, 1393-1399.
https://doi.org/10.1016/j.jtho.2018.05.002
|
[29]
|
Morgensztern, D., Besse, B., Greillier, L., et al. (2019) Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results from the Phase II TRINITY Study. Clinical Cancer Research, 25, 6958-6966. https://doi.org/10.1158/1078-0432.CCR-19-1133
|
[30]
|
Paz-Ares, L., Dvorkin, M., Chen, Y., et al. (2019) Durval-umab plus Platinum-Etoposide versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial. Lancet, 394, 1929-1939. https://doi.org/10.1016/S0140-6736(19)32222-6
|
[31]
|
Reck, M., Mok, T.S.K., Mansfield, A., et al. (2022) Brief Report: Exploratory Analysis of Maintenance Therapy in Patients with Extensive-Stage SCLC Treated First Line with Atezolizumab plus Carboplatin and Etoposide. Journal of Thoracic Oncology, 17, 1122-1129. https://doi.org/10.1016/j.jtho.2022.05.016
|
[32]
|
Liu, X., Xing, H. and Liu, B. (2022) Current Status and Future Perspectives of Immune Checkpoint Inhibitors in Extensive-Stage Small Cell Lung Cancer. American Journal of Cancer Research, 12, 2447-2464.
|
[33]
|
Antonia, S.J., López-Martin, J.A., Bendell, J., et al. (2016) Nivolumab Alone and Nivolumab plus Ipilimumab in Recurrent Small-Cell Lung Cancer (CheckMate 032): A Multicentre, Open-Label, Phase 1/2 Trial. The Lancet Oncology, 17, e270. https://doi.org/10.1016/S1470-2045(16)30098-5
|
[34]
|
Iams, W.T., Shi-uan, E., Meador, C.B., et al. (2019) Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have SCLC with Neurologic Paraneoplastic Syndromes. Journal of Thoracic Oncology, 14, 1970-1981. https://doi.org/10.1016/j.jtho.2019.05.042
|
[35]
|
Chung, H.C., Piha-Paul, S.A., et al. (2020) Pembrolizumab after Two or More Lines of Previous Therapy in Patients with Recurrent or Metastatic SCLC: Results from the KEYNOTE-028 and KEYNOTE-158 Studies. Journal of Thoracic Oncology, 15, 618-627. https://doi.org/10.1016/j.jtho.2019.12.109
|
[36]
|
Ott, P.A., Bang, Y.-J., Piha-Paul, S.A., et al. (2019) T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Pre-dict Efficacy in Patients Treated with Pembrolizumab across 20 Cancers: KEYNOTE-028. Journal of Clinical Oncology, 37, 318-327. https://doi.org/10.1200/JCO.2018.78.2276
|
[37]
|
庞连胜, 赵万春. 外周血淋巴细胞免疫表型检验在恶性肿瘤患者细胞免疫功能评价中的应用价值[J]. 国际免疫学杂志, 2019, 42(3): 280-284.
|
[38]
|
王玲, 邱志敏, 傅颖媛. DC-CIK细胞免疫治疗恶性肿瘤的研究进展[J]. 实用癌症杂志, 2017, 32(2): 345-348.
|
[39]
|
Garon, E.B., Rizvi, N.A., Hui, R., et al. (2015) Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. New England Journal of Medicine, 372, 2018-2028. https://doi.org/10.1056/NEJMoa1501824
|
[40]
|
侯柏村, 刘婷婷, 李涛, 胡毅. LIPI评分与晚期胃癌患者免疫检查点抑制剂治疗疗效及预后的关系[J]. 解放军医学院学报, 2020, 41(5): 436-439+445.
|
[41]
|
Sun, B., Hou, Q., Liang, Y., et al. (2022) Prognostic Ability of Lung Immune Prognostic Index in Limited-Stage Small Cell Lung Cancer. BMC Cancer, 22, Article No. 1233. https://doi.org/10.1186/s12885-022-10351-7
|